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A B S T R A C T
Introduction: In 2011, a homozygous mutation in GOSR2 (c.430G > T; p. Gly144Trp) was reported as a novel
cause of Progressive Myoclonus Epilepsy (PME) with early-onset ataxia. Interestingly, the ancestors of patients
originate from countries bound to the North Sea, hence the condition was termed North Sea PME (NSPME). Until
now, only 20 patients have been reported in literature. Here, we provide a detailed description of clinical and
neurophysiological data of seventeen patients.
Methods: We collected clinical and neurophysiological data from the medical records of seventeen NSPME pa-
tients (5–46 years). In addition, we conducted an interview focused on factors inﬂuencing myoclonus severity.
Results: The core clinical features of NSPME are early-onset ataxia, myoclonus and seizures, with additionally
areﬂexia and scoliosis. Factors such as fever, illness, heat, emotions, stress, noise and light (ﬂashes) all ex-
acerbated myoclonic jerks. Epilepsy severity ranged from the absence of or incidental clinical seizures to fre-
quent daily seizures and status epilepticus. Some patients made use of a wheelchair during their ﬁrst decade,
whereas others still walked independently during their third decade. Neurophysiological features suggesting
neuromuscular involvement in NSPME were variable, with ﬁndings ranging from indicative of sensory neuro-
nopathy and anterior horn cell involvement to an isolated absent H-reﬂex.
Conclusion: Although the sequence of symptoms is rather homogeneous, the severity of symptoms and rate of
progression varied considerably among individual patients. Common triggers for myoclonus can be identiﬁed
and myoclonus is diﬃcult to treat; to what extent neuromuscular involvement contributes to the phenotype
remains to be further elucidated.
1. Introduction
In 2011, a homozygous mutation in the Golgi SNAP Receptor
Complex Member 2 (GOSR2) gene was described as a new cause of
Progressive Myoclonus Epilepsy (PME) with early ataxia [1]. It was [2]
subsequently reported that ancestors of patients with this mutation
came from countries bounding to the North Sea, hence the condition
was termed ‘North Sea’ PME (NSMPE). All patients carried the same
homozygous missense mutation in GOSR2 (c.430G > T, p.Gly144Trp),
a gene encoding a traﬃcking membrane protein involved in the fusion
of vesicles from the endoplasmic reticulum to the cis- Golgi [3]. The
pathogenicity of the p.Gly144Trp mutation so far relies on in vitro
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studies with yeast in which a mutation in bos1, the yeast ortholog of
GOSR2, demonstrated evidence for a (partial) loss of function. Until
now, the underlying mechanism of the homozygous GOSR2 mutation
leading to PME with early-onset ataxia is largely unknown.
The clinical picture of NSPME is characterized by the onset of ataxia
and areﬂexia at a young age, typically followed by the onset of myo-
clonus and epilepsy. Deformities such as scoliosis and a (slightly) ele-
vated creatine kinase (CK) level may additionally be found, but are not
present in every patient. Interestingly, cognitive function appears to be
relatively spared, but NSPME is a very debilitating neurological con-
dition with a progressive nature, and treatment modalities are currently
only symptomatic [1,3–6].
NSPME is part of the group of PMEs, which are rare genetic dis-
orders characterized by myoclonus, seizures, and progressive neurolo-
gical deterioration, particularly ataxia and dementia [7]. The clinical
phenotype of PME overlaps with progressive myoclonus ataxia (PMA),
which usually has a genetic cause as well. PMA is deﬁned as progressive
myoclonus and ataxia, but without prominent dementia and with in-
frequent seizures [8,9]. Based on the NSPME phenotype one can debate
whether it is in fact a PME or PMA phenotype (Van Egmond et al. [4]).
Although most patients reported to date carry the GOSR2 mutation
in homozygous form, recently, the spectrum of observed GOSR2 mu-
tations has expanded. One compound heterozygous GOSR2 mutation
(c.430G > T and c.491_493delAGA) results in a similar clinical phe-
notype with a somewhat milder disease course compared to NSPME
[10]. Interestingly, two other compound heterozygous GOSR2 muta-
tions (c.430G > T and c.336 + 1G > A; c.430G > T and c. 2T > G)
were linked to muscular dystrophy [11,12]. This shows that GOSR2
mutations can be associated with a broader phenotypic spectrum, and
may suggest that the GOSR2 protein has a function in several organ-
systems.
So far, only 20 NSPME patients have been described [1,2,4,5]. Here,
we provide a detailed clinical description of a large NSPME cohort
(n = 17) with the aim of further delineating the clinical phenotype and
functioning of patients. As two other GOSR2 mutations were associated
with muscular dystrophy, we closely looked into possible neuromus-
cular involvement in NSPME in this cohort.
2. Patients and methods
We included all patients with NSPME from three medical centers,
encompassing nine patients previously reported (Boissé Lomax et al.,
Van Egmond et al., Anderson et al. [2,4,5]) and eight new cases.
Fourteen patients were Dutch and three South African, ancestors of the
South African patients originated from Northern Germany. All patients
or their parents consented to participate and the study was performed
in accordance with regulations of the Human Research Ethics Com-
mittees of the University Medical Center Groningen (UMCG), Erasmus
Medical Center Rotterdam (Erasmus MC) and Wits University Donald
Gordon Medical Center Johannesburg (UMCG M17.215724 and
M18.235646, Erasmus MC MEC-2018-1136, Wits University
M1811121).
We systematically collected data from the medical records on initial
presenting signs, motor symptoms, epilepsy, skeletal deformities,
highest CK, brain MRI, clinical neurophysiological investigations and
treatment. We interviewed caregivers about the onset of signs and
symptoms during the last visit of most patients (n = 13). In addition,
we interviewed all patients and/or their caregivers about factors that
inﬂuenced myoclonus severity.
In order to get more insight into neuromuscular involvement in
NSPME, we collected information regarding nerve conduction studies
(NCS) and needle electromyography (EMG). Data on follow-up NCS and
needle EMG were recorded when available. Parameters of NCS included
amplitudes of Sensory Nerve Action Potentials (SNAPs) and Compound
Muscle Action Potentials (CMAPs), and conduction velocities of SNAPs
and CMAPs of patients that underwent conventional warm-up
procedures prior to NCS (n = 6/10); and late responses including so-
leus H-reﬂexes and ulnar, median, tibial and peroneal F-waves.
Parameters of needle EMG included spontaneous muscle activity,
duration, amplitude and shape of Motor Unit Action Potentials
(MUAPs) and their recruitment pattern.
We used SPSS statistics version 23 (Windows) for descriptive sta-
tistics regarding the frequency and mean age onset of symptoms in this
NSPME cohort.
3. Results
We included four pediatric patients and thirteen adult patients with
NSPME (6 female:11 male). Mean age was 25,4 years (range 5–46
years). The homozygous GOSR2 mutation (c.430G > T, p.Gly144Trp)
was conﬁrmed in ﬁfteen patients. In two patients, genetic analysis for
the homozygous GOSR2 mutation has not been performed, because the
mutation was conﬁrmed in their siblings. Supplementary Table 1 dis-
plays clinical characteristics and treatment for all patients.
3.1. Clinical characteristics
Fig. 1 summarizes the clinical course of NSPME with the main
clinical features over time. In most patients (16/17; 94%), ﬁrst signs
were already noticed by parents around the age of 1–4 years and in-
cluded delayed motor development (predominantly delayed walking),
clumsiness, gait disorders, frequent falls, hypotonia, and jerks (all based
on history taking and clinical examination). In six of these patients,
their ﬁrst signs were associated with a period of intercurrent illness/
fever. Initial signs were not fully documented for one patient.
Ataxia was ﬁrst observed on average around the age of 4 years
(range 2–8 years) and was present in all patients. Thereafter myoclonus
started around the age of 6 years (range 3–9 years) and is also present in
all patients. Myoclonus was either generalized or multifocal, present at
rest and action-induced, and stimulus-sensitive. The upper limbs were
more aﬀected than lower limbs, and myoclonus was most prominent
distally in the hands and ﬁngers. In the face, myoclonus was noted
around the mouth and tongue. Speciﬁc triggers, in particular fever,
illness, heat, emotions, stress, noise and light (ﬂashes) all exacerbated
myoclonic jerks. Many patients (13/17; 76%) reported that myoclonus
exacerbated during the night or early in the morning, especially at
waking up.
Most patients developed epileptic seizures over time (n = 15/17;
88%), commonly before their second decade. In one patient, febrile
seizures manifested prior to the diagnosis of myoclonus. Seizure types
Fig. 1. Sequence of clinical features in NSPME over time, displaying the age at
which clinical features were ﬁrst documented. The colored bar depicts the
duration of clinical features. *Age at which patients ﬁrst started to use a
wheelchair. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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included both generalized motor seizures (tonic-clonic and myoclonic)
and generalized non-motor seizures (absences). Some patients (4/17;
24%) reported that in the days preceding a seizure, the intensity of
myoclonus increased and temporarily decreased after a seizure. Seizure
frequency was very variable among the patients with seizures, ranging
from daily to yearly seizures and often depended on environmental
factors, e.g. stress and days with many activities.
Dysarthria (n = 15) manifested mostly during the ﬁrst decade.
Swallowing problems were reported in 7/17 (41%) patients around
their second or third decade. In general, no prominent dementia was
reported in the context of severe neurological decline on motor do-
mains. However, in only one patient a full neuropsychological ex-
amination was performed at the age of 23 years; demonstrating visual-
memory diﬃculties, working-memory diﬃculties and poor ﬂuency with
intact emotion-recognition and planning skills.
Absent reﬂexes were reported in all patients, frequently already
documented between the age of 2–5 years (n = 9/17; 53%). Areﬂexia
was not accompanied by muscle weakness and disturbed sensory
function at a young age.
Scoliosis was documented in 11/17 (65%) patients during their ﬁrst
or second decade. Other deformities included pes cavus (n = 5), pes
planus (n = 1), pes varus (n = 1) and syndactyly (n = 1).
Hypothyroidism was diagnosed in 3/17 (18%) patients (at ages 17–29
years) and treated with levothyroxine in all three.
3.2. Daily functioning
Most patients used a wheelchair (n = 15/17; 88%), either occa-
sionally (e.g. for long distances) or regularly. The age at which patients
ﬁrst started using a wheelchair ranged from 7 to 28 years. Reasons for
starting to use a wheelchair included frequent falls, disturbed balance
and myoclonic jerks. Over time, patients reported to have diﬃculties
with eating and drinking, and expressed the need for assistance in many
activities of daily life, not only with feeding, but also showering and
getting dressed, in line with the progressive nature of the disorder.
3.3. Neurophysiological studies and imaging
3.3.1. Nerve conduction studies and needle electromyography
Previously, Van Egmond et al. [4] reported ﬁndings indicating
sensory neuronopathy and anterior horn cell involvement in NSPME
patients. Here, the follow-up of these patients (n = 5) and ﬁndings of
new patients are described (n = 5). Supplementary Table 2 displays
NCS and needle EMG details.
Sensory and motor NCS were available for 10/17 patients (59%). In
4/10, decreased SNAP amplitudes of upper limbs (median, ulnar and
radial nerves) and lower limbs (peroneal and sural nerves) were found
without a length-dependent distribution. SNAP conduction velocities
were in the normal range to slightly decreased, but in none of the pa-
tients (n = 6/10) in the demyelinating range based on their most recent
NCS (deﬁned<75% of the lower limit of the reference range). The
decreased SNAP amplitudes could ﬁt a sensory polyneuropathy or
sensory neuronopathy. However, based on an absent length-dependent
distribution of decreased SNAP amplitudes, a sensory neuronopathy
was suspected in 4/10. Motor NCS demonstrated normal or slightly
reduced CMAP amplitudes and conduction velocities. F-waves were
present in all patients and showed no abnormalities. Motor NCS ab-
normalities were less pronounced than sensory NCS abnormalities and
were discrepant with needle EMG ﬁndings. Noticeably, H-reﬂexes were
absent in all patients in which this was tested (n = 9). In one patient, a
focal neuropathy of the peroneal nerve was found on NCS.
In 6/10 patients, needle EMG was also available. In 5/6, needle
EMG demonstrated broad polyphasic MUAPs with high amplitudes and
a decreased recruitment pattern (patients ages 12–36 years) in the ti-
bialis anterior muscle, without spontaneous muscle activity. This was
interpreted as a neurogenic pattern, which could ﬁt with sensorimotor
polyneuropathy or anterior horn cell involvement. In three patients
with an aberrant needle EMG, other muscles were additionally tested,
demonstrating a similar neurogenic pattern without a proximal-distal
distribution. In view of the absence of a proximal-distal distribution,
anterior horn cell involvement was suspected in 3/10. In one patient,
no signiﬁcant needle EMG abnormalities were reported at age 13 years.
Follow-up NCS were available in ﬁve patients, demonstrating non-
conclusive ﬂuctuating SNAP amplitudes over time in 4/5. In one pa-
tient, follow-up NCS data was insuﬃcient for interpretation. Follow-up
needle EMGs were available in three patients, demonstrating a slight
increase of the neurogenic pattern in 2/3.
In summary, NCS available in ten patients were indicative of sen-
sory neuronopathy (n = 4) and a focal neuropathy (n = 1), and needle
EMG ﬁndings available in six patients were suspicious of anterior horn
cell involvement (n = 3).
3.3.2. Additional investigations
Electroencephalography (EEG) was performed in 16/17 (94%) pa-
tients, in the youngest patient no EEG had been performed. In most
patients (n = 15/16; 94%) focal (predominantly occipital), multifocal
and generalized epileptiform activity was described; including spikes,
waves, polyspikes, spike wave complexes and poly-spike wave com-
plexes. Additionally, a slow background pattern (n = 11) and a pho-
toparoxysmal-response (n = 7) was documented.
Polymyographies (EEG-EMG recordings) were performed in 7/17
(41%) patients, demonstrating a cortical origin of myoclonus in all
patients. A short burst-duration of< 100 ms was reported, together
with the presence of both positive and negative myoclonus. Back-
averaging (n = 1) and cortico-coherence analysis (n = 1) supported the
cortical origin of myoclonus.
Brain MRIs were performed in 14/17 (82%) patients (age performed
3–36 years) and were normal in all cases except for one, which showed
cerebellar folia-atrophy around the age of 6 years.
3.4. Treatment of myoclonus and seizures
All patients were treated with one or more anti-epileptic drugs, with
the aim of myoclonus suppression and seizure reduction. Only in the
youngest patient clonazepam monotherapy was used to treat myo-
clonus. Combination-therapy consisting of clonazepam (17/17; 100%),
valproic acid (16/17; 94%) and levetiracetam (11/17; 65%) was most
frequently used. Although some patients reported an improvement with
their medication regimes, in most of them myoclonus and/or seizures
were still not satisfactorily controlled. For this reason, two patients
were on a ketogenic diet [6]. Epilepsy severity rapidly progressed in
one patient at age 8 years with 60–80 seizures during the night, which
reduced to 20 seizures per night after starting the ketogenic diet. Four
patients had undergone bilateral deep brain stimulation (DBS) in the
Zona Incerta in the past (Anderson et al. [5]), only in one patient DBS
was still active.
4. Discussion
Here, we describe detailed clinical and neurophysiological ﬁndings
in a large NSPME cohort (n = 17). All patients tested carry the same
homozygous GOSR2 mutation (c.430G > T, p.Gly144Trp) and core-
clinical features encompass early-onset ataxia, myoclonus and seizures
with additional features including areﬂexia and scoliosis. Although the
sequence of symptoms is identical in all patients, symptom severity and
rate of progression varied considerably among individual patients,
which is reﬂected by signiﬁcant diﬀerences in seizure frequency and the
wide range of the age of ﬁrst wheelchair use (7–28 years).
Myoclonus is very prominent in all NSPME patients, interfering with
mobility and daily activities. Negative myoclonus was clinically re-
ported formerly, in this study we provide neurophysiological evidence
for the presence of negative myoclonus [2]. This may well relate to the
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reported frequent falls causing anxiety to walk and the use of a
wheelchair. Noticeably, three patients in our cohort were diagnosed
with hypothyroidism, which has not been reported previously in
NSPME. Whether this belongs to the clinical phenotype or might for
example be due to anti-epileptic drug use (e.g. valproic acid) is un-
known, but clinicians should be alert to this non-neurological sign [13].
Over time, patients may additionally develop dysarthria and dys-
phagia. In contrast to the ﬁndings of Boissé Lomax and colleagues [2],
in which patients developed dysarthria around their mid-to-late twen-
ties, most patients in our cohort already had dysarthria during their ﬁrst
decade. In previous reports on NSPME, the age range of the included
patients was 7–37 years. In our cohort, the youngest patient is 5 years
old and the oldest 46 years old, indicating that despite the progressive
and disabling nature of the disorder patients can survive into middle
age. Previous reports on NSPME described cognitive function remains
relatively preserved, with some memory problems and emotional la-
bility reported around the third decade. In this study, we could not
include substantial data on cognitive function in NSPME patients, but
formal cognitive testing would be of great value in future studies.
Van Egmond et al. [4] previously reported sensory neuronopathy
and anterior horn cell involvement in NSPME patients and our study
builds on their ﬁndings. Although feasibility of NCS and needle EMG is
challenging in NSPME patients due to their frequent myoclonus, we
found that the H-reﬂex was absent in all patients (n = 9) and postulate
three patterns observed: 1. A combination of sensory neuronopathy and
anterior horn cell involvement 2. Anterior horn cell involvement
without sensory neuronopathy 3. An isolated absent H-reﬂex, without
other signiﬁcant NCS and needle EMG ﬁndings. These groups suggest
that grey matter disorganization of the spinal cord is more pronounced
in one patient compared to the other. We speculate that anterior horn
cell involvement explains areﬂexia in NSPME, as in our cohort needle
EMG was aberrant in the majority of patients (n = 5/6), whereas re-
latively less patients displayed signiﬁcant widespread sensory NCS ab-
normalities (n = 4/10). Neuropathology may facilitate further clar-
iﬁcation of neuromuscular abnormalities and remains to be addressed
in future studies on NSPME. Besides areﬂexia, it is unknown what in-
ﬂuence neuromuscular involvement has on the phenotype in NSPME. In
other conditions with anterior horn cell involvement such as Spinal
Muscular Atrophies, scoliosis may be frequent [14]. Whether scoliosis
and other deformities in NSPME are complications of neuromuscular
involvement is left to be elucidated.
The clinical ﬁnding of areﬂexia and NCS- and needle EMG ab-
normalities demonstrate that the eﬀect of GOSR2 mutations is not
conﬁned to the central nervous system but also aﬀects the neuromus-
cular system. Larson et al. described two sisters with hypotonia, pro-
gressive muscle weakness and CK values of up to ~5000. In the oldest
sister, seizures were reported and muscle biopsy demonstrated an active
dystrophic process with hypoglycosylation of alpha-dystroglycan.
Targeted sequencing revealed compound heterozygous GOSR2 muta-
tions (c.430G > T and c. 2T > G) [11]. Moreover, Tsai et al. de-
scribed a 36 week old male with compound heterozygous GOSR2 mu-
tations (c.430G > T and c.336 + 1G > A) with similar clinical
characteristics. His muscle biopsy revealed severe non-dystrophic
changes with normal levels of glycosylated alpha-dystroglycan [12].
Among the group of PMEs with cognitive preservation and the
PMAs (Unverricht-Lundborg disease, ULD; SCARB2; PRICKLE1),
NSPME appears to have the earliest age of onset [15–17] with a more
progressive natural course compared to ULD for instance, in which a
self-limited progression is evident [16]. Magaudda et al. [16] reported
that 70% of their ULD patients were still able to walk independently in
adulthood (n = 20; 26–53 years). In our NSPME cohort, (n = 17; 5–46
years), only 29% were still able to walk independently.
Quite similar to SCARB2 [17], epilepsy severity markedly diﬀers
between individual patients in NSPME where only two patients did not
experience seizures. One is the youngest patient of 5 years old and the
other is a 13 year old boy. Although his EEG showed epileptiform
activity and a photoparoxysmal-response, he has had no clinical sei-
zures so far. He is treated for his myoclonus though and this may have
inﬂuenced seizure onset. On the contrary, ﬁndings in two other patients
illustrate epilepsy may be quite severe in NSPME, even at a young age.
In one patient, epilepsy started at age 7 years and she experienced a
rapid progression of seizure frequency, with up to 60–80 seizures
during the night at age 8 years. This seizure severity has not been re-
ported before in NSPME. The other patient developed an episode with
increased seizure frequency and status epilepticus at age 26 years.
Fever and intercurrent illness appear to have a marked negative
eﬀect on symptoms in NSPME. Parents reported that motor function
(e.g. walking) became more diﬃcult during an episode of intercurrent
illness in their child, and that they felt that after such an episode their
children did not reach their previous level of motor functioning again.
Moreover, parents and patients themselves reported myoclonus wor-
sened during fever/intercurrent illness. For this reason in some patients
a mitochondrial disorder was ﬁrst suspected before the diagnosis
NSPME was made. For patient counseling, it is important to recommend
careful monitoring of fever and intercurrent illness and take preventive
measures such as antipyretic therapy. Triggers identiﬁed for symptom
exacerbation in NSPME overlap considerably with triggers found in
patients with ATP1A3, GNAO1 and SCNA1 mutations. Besides factors
such as stress and strong emotions, fever and increased environmental
temperature have been reported to provoke or exacerbate symptoms in
these conditions as well [18–22]. Particularly the latter factors raise
questions with regards to what mechanism underpins the role of ele-
vated body temperature and perhaps that of inﬂammation.
Although GOSR2 plays a crucial role in the secretory pathway
during the fusion of vesicles with the cis-Golgi in eukaryotic cells, it is
puzzling why mutations in GOSR2 lead to a predominantly neurological
phenotype. Jepson et al. postulated that in particular the nervous
system is vulnerable to disturbances in ER-to-Golgi-traﬃcking due to its
extensive volume of membrane traﬃcking. In addition, they hypothe-
sized that GOSR2 mutations may lead to an imbalance of ion channel
activity attributable to defective post-Golgi traﬃcking of ion channels,
subsequently inﬂuencing neuronal excitability and neurotransmitter
release [23,24]. Recent work by Lambrechts et al. sheds further light on
the predominantly neurological phenotype and suggests a role for glia
in the pathophysiology of NSPME [25].
In conclusion, NSPME is characterized by a uniform sequence of
early-onset ataxia, myoclonus and epilepsy with additional distinctive
features including areﬂexia and deformities such as scoliosis. We report
that there is a considerable variability in symptom severity and pro-
gression. Neurophysiological features regarding neuromuscular in-
volvement in NSPME are also variable, but indicate involvement of the
peripheral nervous system. Treatment options are symptomatic and do
not satisfactorily control symptoms, which signiﬁcantly inﬂuences daily
functioning of patients with NSPME. Currently, our understanding of
the GOSR2 function is limited, and the mechanism behind the (mainly
neurological) clinical phenotypes of GOSR2 mutations even more so.
Elucidating the exact function of GOSR2 and the pathophysiology of
GOSR2-related disorders hopefully contribute to a mechanism-based
treatment of NSPME and related disorders.
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